Bio-Rad Laboratories, Inc. Class A Common Stock vs Goodyear Tire & Rubber Co — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $358.69 (market cap $9.43B), while Goodyear Tire & Rubber Co trades at $5.97 (market cap $1.75B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 5.4× Goodyear Tire & Rubber Co's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Goodyear Tire & Rubber Co nearer its low. Which is the better fit depends on your goals.
| BIO | GT | |
|---|---|---|
Market Cap | $9.43B | $1.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $356.25 | $10.54 |
52-Week Low | $241.71 | $5.58 |
Enterprise Value | $9.18B | $9.11B |
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $357.58, up 0.86% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, the company reported a Q2 2026 earnings beat with EPS of $2.62 versus $1.75 expected, and net income for 2025 reached $759.9 million, a significant recovery from prior years. Analyst sentiment is positive with a consensus buy rating and a $350 price target, though the P/E ratio of 43.39 suggests a premium valuation.
The outlook for BIO is cautiously optimistic, driven by earnings momentum and improving cash flow, but risks include high valuation, competitive pressures in life sciences, and reliance on academic research markets. Upside potential exists if international revenue trends strengthen, but investors should monitor margin sustainability and debt levels, which have improved but remain a focus.
Goodyear Tire & Rubber (GT) trades at $5.955, down 1.24% on the day, with a bearish technical signal and mixed analyst sentiment. The company reported a Q2 2026 loss of $0.61 per share, beating expectations but reflecting ongoing volume pressure. Revenue trends show a decline from $20.8B in 2022 to $17.7B projected for 2026, with negative net income margins. Valuation metrics appear attractive with P/E of 4.69 and P/B of 0.62, but profitability remains challenged with ROE at -63.93%.
The outlook remains cautious as Goodyear faces persistent volume declines and competitive pressures, though cash flow improvements and Asia Pacific gains provide some support. Investment opportunity exists in the deeply discounted valuation if operational turnaround succeeds, but risks include continued market share erosion and high debt levels. Analyst consensus shows 34.6% buy ratings with 50% recommending hold, indicating Wall Street's wait-and-see approach.
Trailing returns across standard periods
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →